Knoll Capital Management, LLC holds a focused book of 37 stocks worth $180.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Sprott Physical Gold Trust and trimmed Kinross Gold Corp. Their largest long position is Biohaven Pharmaceutical Hold at 11% of the equity book.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
88% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Knoll Capital Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| MORGAN STANLEY | 37 / 37 | $15.8B |
| UBS Group AG | 36 / 37 | $6.6B |
| ROYAL BANK OF CANADA | 35 / 37 | $9.8B |
| BANK OF AMERICA CORP /DE/ | 34 / 37 | $13.4B |
| JPMORGAN CHASE & CO | 34 / 37 | $13.3B |
| GOLDMAN SACHS GROUP INC | 34 / 37 | $6.2B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 34 / 37 | $1.3B |
| BNP PARIBAS FINANCIAL MARKETS | 33 / 37 | $1.4B |
Ranked by the share of each fund's own book sitting in the names it shares with Knoll Capital Management, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Biohaven Pharmactl Hldg Co COM | $19.7M | 2.33M | 10.9% | —Held | |
| 2 | Sprott physical gold Trust Physical Gold Tr | $13.7M | 387.1K | 7.6% | ▲New New position | |
| 3 | Royal Gold Inc. COM | $13.4M | 52.8K | 7.5% | —Held | |
| 4 | MeiraGTX Holdings COM | $10.8M | 1.25M | 6.0% | —Held | |
| 5 | Agnico Eagle Mines Ltd COM | $10.7M | 52.8K | 5.9% | —Held | |
| 6 | Kinross Gold Corp COM | $9.8M | 320.0K | 5.4% | ▼−22% Reduced · −90K sh | |
| 7 | Aldeyra Therapeutics Inc COM | $9.3M | 5.48M | 5.1% | —Held | |
| 8 | Seabridge Gold Inc COM | $9.0M | 317.0K | 5.0% | —Held | |
| 9 | Franco Nev Corp COM | $7.9M | 32.0K | 4.4% | ▲+28% Added · +7K sh | |
| 10 | SSR Mining In COM | $7.2M | 245.0K | 4.0% | —Held | |
| 11 | Elicio Therapeutics Inc COM | $6.7M | 630.9K | 3.7% | —Held | |
| 12 | Entera Bio Ltd SHS | $6.5M | 5.88M | 3.6% | —Held | |
| 13 | Nuvation Bio Inc COM CL A | $6.4M | 1.50M | 3.6% | —Held | |
| 14 | Centerra Gold Inc COM | $6.4M | 359.0K | 3.5% | ▼−28% Reduced · −138K sh | |
| 15 | Pan American Silver COM | $5.5M | 100.0K | 3.0% | —Held | |
| 16 | Sprott Physical silver Trust Physical Silver | $5.4M | 222.2K | 3.0% | ▲New New position | |
| 17 | Ocular Therapeutix Inc. COM | $5.1M | 600.4K | 2.8% | —Held | |
| 18 | Triple Flag Precious Metals COM | $4.0M | 115.0K | 2.2% | ▲+96% Added · +56K sh | |
| 19 | Gold RTY Corp COM | $3.6M | 1.00M | 2.0% | ▲New New position | |
| 20 | Alamos Gold Inc COM CL New | $2.2M | 50.0K | 1.2% | —Held | |
| 21 | Abeona Therapeutics COM NEW | $2.2M | 485.5K | 1.2% | ▲+106% Added · +250K sh | |
| 22 | New Pac Metals Corp COM | $2.0M | 485.0K | 1.1% | —Held | |
| 23 | Coeur Mining Inc COM NEW | $1.8M | 96.1K | 1.0% | —Held | |
| 24 | iSHares US Aerospace & Defense US AER DEF ETF | $1.7M | 7.7K | 0.9% | —Held | |
| 25 | Philip Morris Intl. Inc COM | $1.7M | 10.0K | 0.9% | —Held | |
| 26 | Wheaton Precious Metals Corp COM | $1.6M | 12.5K | 0.9% | —Held | |
| 27 | Northrop Grumman Corp COM | $1.5M | 2.2K | 0.8% | —Held | |
| 28 | Booz Allen Hamilton HLDG COR CL A | $1.0M | 13.0K | 0.6% | —Held | |
| 29 | Elemental RTY Corp COM NEW | $943K | 50.0K | 0.5% | ▲New New position | |
| 30 | Versamet Royalties Corp COM NEW | $634K | 66.6K | 0.4% | ▲New New position | |
| 31 | Dakota Gold Corp COM | $621K | 122.9K | 0.3% | —Held | |
| 32 | Amrize LTD SHS | $514K | 9.2K | 0.3% | ▲New New position | |
| 33 | Altimmune Inc COM NEW | $493K | 160.0K | 0.3% | ▼−86% Reduced · −962K sh | |
| 34 | Cardiol Therapeutics Inc COM Cal A | $135K | 100.0K | 0.1% | —Held | |
| 35 | Pharming Group NV SPON ADS | $68K | 4.1K | 0.0% | ▲New New position | |
| 36 | Orgenesis, Inc. COM | $30K | 50.6K | 0.0% | —Held | |
| 37 | OR Royalties COM SHS | $9K | 225.0K | 0.0% | ▲New New position |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1325083/holdings"
Use Arkolith to show Knoll Capital Management, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.